Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib

European Journal of Cancer

Volumn 50, Issue 5, 2014, Pages 981-986

  Shinagare, Atul B ^a   Jagannathan, Jyothi P ^b   Kurra, Vikram ^b   Urban, Trinity ^b   Manola, Judith ^b   Choy, Edwin ^b   Demetri, George D ^b   George, Suzanne ^b   Ramaiya, Nikhil H ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Choi; Gastrointestinal stromal tumour; RECIST; Regorafenib; Tumour response criteria

Indexed keywords

IMATINIB; REGORAFENIB; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

CHOI; GASTROINTESTINAL STROMAL TUMOUR; RECIST; REGORAFENIB; TUMOUR RESPONSE CRITERIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHENYLUREA COMPOUNDS; PIPERAZINES; PROSPECTIVE STUDIES; PYRIDINES; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION;

EID: 84896723620     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.11.037     Document Type: Article

References (17)

1. S. Hirota, K. Isozaki, Y. Moriyama, K. Hashimoto, T. Nishida, and S. Ishiguro et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 5350 1998 577 580
2. H. Joensuu, P.J. Roberts, M. Sarlomo-Rikala, L.C. Andersson, P. Tervahartiala, and D. Tuveson et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 14 2001 1052 1056
3. B.J. Druker Molecularly targeted therapy: have the floodgates opened? Oncologist 9 4 2004 357 360
4. V.P. Koshenkov, and S.E. Rodgers Adjuvant therapy of gastrointestinal stromal tumors Curr Opin Oncol 24 4 2012 414 418
5. F.E. Pedroso, C.P. Raut, H. Xiao, C.J. Yeo, and L.G. Koniaris Has the survival rate for surgically resected gastric gastrointestinal stromal tumors improved in the tyrosine kinase inhibitor era? Ann Surg Oncol 19 6 2012 1748 1758
6. G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, and P.J. Roberts et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 2002 472 480
7. G.D. Demetri, A.T. van Oosterom, C.R. Garrett, M.E. Blackstein, M.H. Shah, and J. Verweij et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 9544 2006 1329 1338
8. S. George, Q. Wang, M.C. Heinrich, C.L. Corless, M. Zhu, and J.E. Butrynski et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial J Clin Oncol 30 19 2012 2401 2407
9. G.D. Demetri, P. Reichardt, Y.-K. Kang, J.-Y. Blay, P. Rutkowski, and H. Gelderblom et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 9863 2013 295 302
10. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1 1981 207 214
11. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
12. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
13. H. Choi, C. Charnsangavej, S.C. Faria, H.A. Macapinlac, M.A. Burgess, and S.R. Patel et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 13 2007 1753 1759
14. R.S. Benjamin, H. Choi, H.A. Macapinlac, M.A. Burgess, S.R. Patel, and L.L. Chen et al. We should desist using RECIST, at least in GIST J Clin Oncol 25 13 2007 1760 1764
15. C.D. Blanke, G.D. Demetri, M. von Mehren, M.C. Heinrich, B. Eisenberg, and J.A. Fletcher et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 4 2008 620 625
16. D.G.B.J. Altman Practical statistics for medical research 1991 Chapman and Hall London
17. A. Le Cesne, M. Van Glabbeke, J. Verweij, P.G. Casali, M. Findlay, and P. Reichardt et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial J Clin Oncol 27 24 2009 3969 3974